🔴 Tscan Therapeutics is trading 5.53% down in after-hours trading as rising Treasury yields pressure growth stocks

Tscan Therapeutics is trading 5.53% down now at $0.78 as broad risk-off selling pressures U.S. equities on August 18, 2026.

• No new company-specific announcement, filing, analyst action, or clinical catalyst was identified for the date.
• The latest material update was August 12 second-quarter results: $1.05 million revenue and a narrower-than-expected adjusted loss, though revenue substantially missed estimates.
• Rising Treasury yields and geopolitical uncertainty pressured technology and growth stocks.